je.st
news
Tag: therapy
Wave of interest in gene therapy brings Voyager a new $60M investment
2015-04-14 00:09:04| Biotech - Topix.net
It's a testament to the sudden resurgence of interest in gene therapy that a week after Dutch biotech uniQure NV announced a major investment from drug giant Bristol-Myers Squibb, Cambridge-based Voyager Therapeutics announced one of the biggest venture rounds of funding this year to date.
Tags: interest
investment
therapy
wave
Patent dispute settlement to benefit Penn cancer therapy partnership
2015-04-08 13:56:58| Biotech - Topix.net
Novartis Pharmaceutical Corp. settled its patent dispute with Juno Therapeutics, removing any potential litigation obstacles from the immunotherapy partnership between Novartis and the University of Pennsylvania. The Wall Street Journal reported Novartis will pay Seattle-based Juno $12.25 million, plus undisclosed future milestone payments and royalties, to resolve the dispute.
Tags: benefit
partnership
cancer
therapy
Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination with Anti-PD-1 Therapy, KEYTRUDA (pembrolizumab), for the Treatment of Advanced Prostate Cancer
2015-04-08 13:30:05| Merck.com - Product News
Dateline City: PRINCETON, N.J., and KENILWORTH, N.J. KEYNOTE-046 is the second trial initiated to evaluate KEYTRUDA, and the first-in-human study of ADXS-PSA, for prostate cancer Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA (ADXS31-142), an investigational Lm-LLO immunotherapy, and KEYTRUDA (pembrolizumab), the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC). Language: English read more
Grazoprevir/Elbasvir, Mercks Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations; New Phase 2 and 3 Data in Multiple HCV Patient Types to be Presented at The International Liver CongressTM 2015
2015-04-08 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Congress Highlights Include Results from Trials in a Wide Range of HCV Patients -- Patients with Chronic Kidney Disease, HIV Co-infection, Cirrhosis, and Prior Treatment Failures Company Remains on Track for NDA Filing with the U.S. FDA During First Half of 2015 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that grazoprevir/elbasvir, an investigational single tablet regimen for the treatment of chronic hepatitis C virus (HCV) infection, has received two new Breakthrough Therapy designations from the U.S. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 908-740-1871orInvestors:Joe Romanelli, 908-740-1879Justin Holko, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
data
international
types
Varian Medical Systems Selected to Equip Two National Proton Therapy Centers in England
2015-03-16 11:31:15| Industrial Newsroom - All News for Today
CRAWLEY, England Varian Medical Systems (NYSE: VAR) today announced that it has been selected to equip and service two new national proton therapy centers in England with the Varian ProBeam proton therapy system. Under a public tender, Varian was selected as the preferred supplier to provide equipment and...
Tags: national
systems
selected
medical
Sites : [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] next »